Stifel Starts Spark Therapeutics (ONCE) at Buy
- Wall Street rises, buoyed by economic data; Dow sets high
- Twitter (TWTR) 'Takeover Money' Moves On as 'Trump Money' Moves In
- Amazon (AMZN) Could Open Over 2,000 Brick-and Mortar Groceries if Tests Succeed - DJ; Kroger (KR) on Watch
- Buy Any Seasonal Market Weakness Ahead of Year End Rally - Oppenheimer (SPY)
- After-Hours Stock Movers 12/05: (TXMD) (COUP) (BOBE) Higher; (SB) (LXRX) (STWD) Lower (more...)
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Stifel initiated coverage on Spark Therapeutics (NASDAQ: ONCE) with a Buy rating and a price target of $73.00.
Shares of Spark Therapeutics closed at $57.55 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Spark Therapeutics (ONCE) SPK-9001 FIX Levels Still Best-in-Class But More Steroid Use - Jefferies
- Credit Suisse Assumes The TJX Companies (TJX) at Neutral
- BofA/Merrill Lynch Resumes PPG Industries (PPG) at Buy
Create E-mail Alert Related CategoriesNew Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!